{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:55:33Z","timestamp":1789239333899,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":141,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:p>\n                    <jats:bold>Objective<\/jats:bold>\n                    \u2002To assess, in a systematic review, the effectiveness of intravesical bacillus Calmette\u2010Gu\u00e9rin (BCG) in preventing tumour recurrence in patients with medium\/high risk Ta and T1 bladder cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods<\/jats:bold>\n                    \u2002An electronic database search of Medline, Embase, DARE, the Cochrane Library, Cancerlit, Healthstar and BIDS was undertaken, plus hand searching of the Proceedings of ASCO, for randomized controlled trials, in any language, comparing transurethral resection (TUR) alone with TUR followed by intravesical BCG in patients with Ta and T1 bladder cancer.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    \u2002The search identified 26 publications comparing TUR with TUR\u2003+\u2003BCG. Six trials were considered acceptable, representing 585 eligible patients, 281 in the TUR\u2010alone group and 304 in the TUR\u2003+\u2003BCG group. The major clinical outcome chosen was tumour recurrence. The weighted mean log hazard ratio for the first recurrence, taken across all six trials, was \u22120.83 (95% confidence interval \u22120.57 to \u22121.08,\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001), which is equivalent to a 56% reduction in the hazard, attributable to BCG. The Peto odds ratio for patients recurring at 12\u2003months was 0.3 (95% confidence interval of 0.21\u20130.43,\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.001), significantly favouring BCG therapy. Manageable toxicities associated with intravesical BCG were cystitis (67%), haematuria (23%), fever (25%) and urinary frequency (71%). No BCG\u2010induced deaths were reported.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    \u2002TUR with intravesical BCG provides a significantly better prophylaxis of tumour recurrence in Ta and T1 bladder cancer than TUR alone. Randomized trials are still needed to address the issues of BCG strain, dose and schedule, and to better quantify the effect on progression to invasive disease.\n                  <\/jats:p>","DOI":"10.1046\/j.1464-410x.2001.02306.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:03:41Z","timestamp":1047351821000},"page":"209-216","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":261,"title":["A systematic review of intravesical bacillus Calmette\u2010Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer"],"prefix":"10.1111","volume":"88","author":[{"given":"M.D.","family":"Shelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kynaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Court","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Coles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Burgon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.10.682"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(99)00015-0"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(99)00019-8"},{"key":"e_1_2_6_5_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavity bacillus Calmette\u2010Guerin in the treatment of superficial bladder tumours","volume":"137","author":"Morales A","year":"1976","journal-title":"J Urol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","unstructured":"HerrH&IntravesicalBCG.Current results natural history and implications for urothelial cancer prevention.J Cellular Biochem1992;Suppl. 161:112\u20139","DOI":"10.1002\/jcb.240501322"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1995.tb00476.x"},{"key":"e_1_2_6_8_2","first-page":"435","article-title":"Resultat du traitement des tumeurs superficielles de la vessie par resection transurethrale seule et resection transurethrale suivie d'instillation endovesicale de bacille Calmette\u2010Guerin","volume":"24","author":"Chopin D","year":"1990","journal-title":"Ann Urol"},{"key":"e_1_2_6_9_2","first-page":"1851","article-title":"BCG Immunotherapia a feluletes holyagtumorok adjuvans kezeleseben","volume":"134","author":"Somogyi L","year":"1993","journal-title":"Orvosi Hetilap"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0022-5347(17)41701-0","article-title":"Prophylactic maltose tetrapalmitate and bacillus Calmette\u2010Guerin immunotherapy of recurrent superficial bladder tumours: preliminary report","volume":"140","author":"Ibrahiem El H","year":"1988","journal-title":"J Urol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6923.257"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.3.441"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65673-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)46972-2"},{"key":"e_1_2_6_15_2","first-page":"69","volume-title":"International Society of Urological Reports: Immunology of Urological Tumours.","author":"Pagano F","year":"1990"},{"key":"e_1_2_6_16_2","first-page":"47","article-title":"Intravesical administration of bacillus Calmette\u2010Guerin in patients with recurrent superficial carcinoma of the urinary bladder: a report of a prospective, randomised trial","volume":"69","author":"Pinsky C","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000281695"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.5980\/jpnjurol1989.81.997"},{"key":"e_1_2_6_19_2","first-page":"503","article-title":"BCG a baja dosis en la terapia de las neoplasias superficiales vesicales","volume":"42","author":"Bassi PF","year":"1990","journal-title":"Arch Esp Urol"},{"key":"e_1_2_6_20_2","first-page":"356","article-title":"Treatment of superficial bladder cancer with intravesical BCG","volume":"160","author":"Camacho F","year":"1980","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-199707000-00017"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830401)51:7<1323::AID-CNCR2820510724>3.0.CO;2-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(85)90525-4"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45604-7"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.9.1450"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1404"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55282-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<82::AID-CNCR2820480117>3.0.CO;2-Z"},{"key":"e_1_2_6_29_2","first-page":"315","volume-title":"Immunotherapy of Human Cancer.","author":"Lamm D","year":"1982"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)53283-8"},{"key":"e_1_2_6_31_2","first-page":"253","volume-title":"EORTC Genitourinary Group Monographs 6, BCG in Superficial Bladder Cancer","author":"Pagano F","year":"1989"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37707-8"},{"key":"e_1_2_6_33_2","first-page":"309","volume-title":"Immunotherapy of Human Cancer.","author":"Pinsky C","year":"1982"},{"key":"e_1_2_6_34_2","first-page":"27","volume-title":"International Society of Urological Reports, Immunotherapy of Urological Tumours.","author":"Rubben H","year":"1990"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)36282-1"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000019664"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02550276"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45606-0"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.125"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(95)00287-S"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68208-0"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.2001.02306.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-410x.2001.02306.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-410x.2001.02306.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:14:59Z","timestamp":1761761699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-410x.2001.02306.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1046\/j.1464-410x.2001.02306.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02306.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]},"assertion":[{"value":"2001-12-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}